title: Bullous hemorrhagic dermatosis at distant sites: a report of 2 new cases due to enoxaparin injection and a review of the literature.
abstract: Enoxaparin is a low-molecular-weight heparin used in the prevention and treatment of pulmonary thromboembolism and other thrombotic disorders. The most common adverse reactions to enoxaparin are ecchymosis, skin necrosis, urticaria, angioedema, and eczema. The first 2 cases of bullous hemorrhagic dermatosis in areas distant from heparin injection sites were described in 2006. We present the cases of 2 men, aged 68 and 78 years, with progressive, advanced-stage lung cancer, who consulted with bullous hemorrhagic lesions without associated symptoms. Both patients reported that the lesions had appeared after initiation of heparin therapy at therapeutic doses. In our review of the literature, we found just 7 cases of heparin-induced bullous hemorrhagic dermatosis. We report a further 2 cases, caused by enoxaparin, in which treatment was continued and in which the lesions resolved in 2 to 3 weeks.
authors.affiliation: Servicio de Dermatología, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, España. cvillanueva.hflr@salud.madrid.org
authors.forename: C A
authors.initials: CA
authors.lastname: Villanueva
authors.forename: L
authors.initials: L
authors.lastname: Nájera
authors.forename: P
authors.initials: P
authors.lastname: Espinosa
authors.forename: J
authors.initials: J
authors.lastname: Borbujo
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D017984:Enoxaparin / Q000009:adverse effects*; D006470:Hemorrhage / Q000139:chemically induced* / Q000150:complications / Q000473:pathology; D006801:Humans; D008297:Male; D012872:Skin Diseases, Vesiculobullous / Q000139:chemically induced* / Q000150:complications / Q000473:pathology
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin